Acute Bioprosthetic Mitral Valve Thrombosis: An Unfortunate Collision of Prothrombotic Risk Factors

Nicole M. Quattrocchi, BA, Jonathan M. Hemli, MD, S. Jacob Scheinerman, MD, Nirav C. Patel MD

Department of Cardiovascular and Thoracic Surgery, Lenox Hill Hospital/Northwell Health, New York, New York, USA

ABSTRACT

Subclinical and clinical thrombosis of bioprosthetic cardiac valves is more common than has been previously recognized. We present a unique case of acute thrombosis of a bioprosthetic mitral valve in a 40-year-old female patient undergoing hormonal stimulation as part of in vitro fertilization therapy, who also had concomitant protein C deficiency that was undiagnosed at the time. To the best of our knowledge, this is the first reported case of acute bioprosthetic valve thrombosis in this complex thrombophilic milieu, and suggests the need for increased screening for prothrombotic risk factors in female patients with bioprosthetic valves before they commence gonadotropin stimulation therapy.

INTRODUCTION

Bioprosthetic valve thrombosis, once thought to be a relatively rare clinical entity, is now becoming more commonly recognized, particularly in the current era of transcatheter valve and valve-in-valve therapy [Sachdev 2018]. Patients with subclinical bioprosthetic valve thrombosis may be essentially asymptomatic, with the diagnosis only being made incidentally during routine echocardiography; some of these individuals may be able to be adequately managed by anticoagulation therapy alone [Nishimura 2017]. By contrast, acute valve thrombosis can present with potentially devastating clinical consequences, requiring emergent intervention.

The hypercoagulability associated with gonadotropin therapy during in vitro fertilization (IVF) therapy is well described [Sennström 2017]. We discuss a case of acute bioprosthetic mitral valve thrombosis in the setting of a heretofore unreported combination of IVF and protein C deficiency.

CASE REPORT

A 40-year-old female with a background of rheumatic heart disease and prior mitral valve repair underwent subsequent mitral valve replacement (MVR) five years thereafter with a stented porcine bioprosthesis. Regular clinical follow-up was rigorously maintained, and the patient remained asymptomatic, with a well-functioning bioprosthetic valve repeatedly demonstrated on routine serial echocardiograms.

Two years after her mitral valve replacement, the patient expressed a desire to undergo in vitro fertilization therapy. She had previously undergone numerous cycles of IVF treatment after her initial mitral valve repair procedure, without cardiac complication, although she failed to conceive at that time. Dobutamine stress echocardiography was undertaken in an attempt to unmask any subclinical valvular or left ventricular dysfunction that could become apparent in the setting of the higher metabolic demand incurred by pregnancy; the test failed to demonstrate any significant abnormalities, and the patient began receiving injections of leuprolide acetate.

A few days after commencing gonadotropin therapy, the patient presented to our institution after a 48-hour history of worsening dyspnea. Upon admission, she was found to be in frank pulmonary edema, with clinical and metabolic evidence of a low cardiac output syndrome. After emergency endotracheal intubation and institution of inotrope and pressor support, transesophageal echocardiography demonstrated multiple large masses on her bioprosthetic mitral valve leaflets, with severely restricted leaflet motion and very little flow through the valve itself (Figure 1; Video 1 https://vimeo.com/346872643). Due to progressive clinical deterioration,
veno-arterial extracorporeal membrane oxygenation (ECMO) was instituted via a femoral approach.

After a 24-hour period of resuscitation on ECMO, the patient underwent further reoperative mitral valve surgery. Her bioprosthetic mitral valve was found to be essentially overgrown by multiple large thrombi, particularly on the ventricular aspect of the valve leaflets (Figures 2 and 3). A new stented porcine bioprosthetic valve was implanted without complication, and the patient was successfully weaned from extracorporeal circulatory support.

Hematologic investigation during the postoperative period revealed that the patient’s serum protein C levels were 55 percent of normal, consistent with a diagnosis of protein C deficiency. She was maintained on anticoagulation therapy. The patient ultimately made an uncomplicated recovery but was advised against any further attempts at IVF therapy.

**DISCUSSION**

The exact mechanisms underlying thrombosis of bioprosthetic valves are not, as yet, well elucidated, although the phenomenon is thought to be multi-factorial in etiology, and is likely a consequence of local hemodynamic and circulatory forces around the valve itself, coupled with various systemic patient factors, such as atrial fibrillation, obesity, diabetes mellitus, chronic renal insufficiency, smoking, anemia, and a spectrum of other low-flow states [Puri 2017]. The incidence of bioprosthetic valve thrombosis undoubtedly remains lower than that of mechanical prostheses, yet it is more common than has been previously recognized. In one of the larger series reported to date, Egbe et al identified valve thrombosis in 11.6% of 397 explanted bioprosthetic valves; more specifically, 12.7% of mitral valves demonstrated histologically proven thrombosis [Egbe 2015]. A recent study by Basra and colleagues utilized four-dimensional computed tomography to identify leaflet thrombosis in 30.9% of transcatheter aortic valve replacement (TAVR) patients and in 32.6% of patients who had undergone traditional surgical aortic valve replacement, all of whom were now presenting with either clinical or echocardiographic indicators suspicious for progressive valvular dysfunction [Basra 2018].

Bioprosthetic valves tend to be the implant of choice in women of child-bearing age that require valve replacement. Despite the increasing worldwide use of assisted reproductive technologies over the past decade [Toner 2016; Kushnir 2017], including gonadotropin stimulation, which has been consistently and reproducibly associated with an elevated risk of vascular thrombosis [Gurunath 2018], there has been only one case report to date of bioprosthetic mitral valve thrombosis in a female patient undergoing IVF therapy [Abazid 2018]. Unfortunately, not only did our patient receive hormonal stimulation, she was ultimately found to also have protein C deficiency, an independent marker for thromboembolic phenomena. To the best of our knowledge, this is the first description of this unlucky constellation of risk factors contributing to acute bioprosthetic valve thrombosis and circulatory collapse.

Interestingly, our patient had previously undergone IVF therapy after her index mitral valve repair surgery some years prior, without clinical or echocardiographic evidence of valvular thrombosis. Although her valve repair did ultimately fail, necessitating mitral valve replacement, there was no evidence of thrombus on the native valve leaflets or on the annuloplasty ring at the time of this operation; it was not until she had a complete bioprosthetic valve in situ that she seemed to have the requisite substrate for acute obstructive thrombosis, potentiated by underlying protein C deficiency and hormonal stimulation.

**Conclusion**

Bioprosthetic valve thrombosis is more common than has been previously recognized. Acute valve thrombosis is potentially life-threatening and warrants emergent intervention, be it...
surgery, lytic or transcatheter therapy. To the best of our knowledge, this is the first case reported of acute bioprosthetic mitral valve thrombosis in a patient undergoing IVF therapy who also had concomitant protein C deficiency. Given the inherent prothrombotic risks associated with hormonal stimulation, we suggest that all patients with bioprosthetic valves be screened for an underlying thrombophilia before commencing therapy.

**REFERENCES**


